STEVEN MONROE LIPKIN
CURRICULUM VITAE

SUMMARY

- I am Director of the Weill Cornell Medical College Adult and Cancer Genetics Clinic, where I practice as a Clinical Geneticist and supervise Genetic Counselors in the Departments of Medicine and Genetic Medicine, and Director of the Program in Mendelian Genetics.
- I am a Vice Chair for Medicine, Weill-Cornell Department of Medicine, where I lead a ~$115MM annual revenue research enterprise portfolio.
- I am a physician-scientist who has published in Cell, Science, Cell Stem Cell, Nature Biotechnology, Nature Genetics, Genes and Development, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation, among others.
- I can effectively communicate complex medical issues to the public. I am author of "The Age of Genomes," a well-received book reviewed in the *NY Times*, have been quoted as a medical technology KOL in *The Wall Street Journal* and other media publications, and have participated as medical technology KOL presenting at lay conferences.
- I direct a translational research laboratory that uses massively parallel sequencing, computational biology, mouse models, cell culture and genomics to understand the contribution of genetics to, and mechanisms of, hereditary genetic syndromes. I have been PI on two NCI sponsored Phase I clinical trials and am currently co-Investigator on two additional NCI sponsored Phase I clinical trials.
- I discovered and mechanistically characterized MLH3, a DNA mismatch repair gene colorectal polyposis and cancer predisposition gene.
- I identified or co-identified 6 B cell malignancy predisposition genes.
- I created the first human cancer cell model in immune proficient mice.
- I have directed a NIH Contract Consortium that cumulatively spent more than $12 million over the past five years and currently have an NCI Moonshot U01 and other grants.
- I am PI of the NCI Center for LNP RNA Cancer Immunoprevention.
- I am currently co-leading an international effort to develop and validate a cancer immunoprevention vaccine for Lynch syndrome.

A. GENERAL INFORMATION

Required Information:

Name: First, Middle, Last	Steven M. Lipkin, MD, PhD
Office address:	413 East 69th Street Lab - 7th Floor Room 702 New York, NY 10021
Office telephone:	646-962-6333
Work Email:	stl2012@med.cornell.edu
Citizenship:	USA

B. EDUCATIONAL BACKGROUND

1. Academic Degree:

Degree	Institution Name	Dates attended	Year Awarded
BA	Princeton University Princeton NJ	9/1982-6/1986	1986
MD/PhD	University of California La Jolla, San Diego	9/1986-6/1995	1995

2. Post-doctoral training:

Title	Institution	Dates held
Internship and Residency (Medicine)	Duke University Medical Center Durham, NC	1995-1997
Clinical Genetics Fellowship	National Human Genome Research Institute (NIH) Bethesda, MD	1997-2000
Post-doctoral fellow (Francis Collins Post-doc Advisor)	National Human Genome Research Institute (NIH) Bethesda, MD	2000-2001

C. LICENSURE, BOARD CERTIFICATION, MALPRACTICE

1. Licensure:

a. State	Number	Date of issue	Date of last registration
California	A75820	07/2001	04/2008 (on leave)
New York	252237	04/2009	04/2017

b. If no license:	
1. 1. Do you have a temporary certificate?	N/A
2. Have you passed the examination for foreign medical school graduates?	N/A

2. Board Certification

Full Name of Board	Certificate #	Dates of Certification (mm/dd/yyyy) –
American Board of Medical Genetics (ABMG)	99094	4/30/1999

D. PROFESSIONAL POSITIONS AND EMPLOYMENT

1. Academic positions

Title	Institution name and location	Dates held
Assistant Professor of Medicine	Department of Medicine University of California, Irvine Irvine, CA	2001-2007
Associate Professor of Medicine, with Tenure	Department of Medicine University of California, Irvine Irvine, CA	2007-2009
Associate Professor of Genetic Medicine	Department of Genetic Medicine Weill Cornell Medical College New York, NY	3/01/2009-Present
Associate Professor of Medicine	Department of Medicine Weill Cornell Medical College New York, NY	3/01/2009-2/29/2015
Adjunct Professor of Medicine,	School of Basic Medical Sciences, Beijing University	2013-2018
Professor of Medicine	Department of Medicine Weill Cornell Medical College New York, NY	03/01/2015-Present
Gladys and Roland Harriman Associate Professor of Medicine	Department of Medicine Weill Cornell Medical College New York, NY	4/2016-Present

2. Hospital positions

Title	Institution	Dates held
Attending Physician	New York Presbyterian Hospital New York, NY	03/01/2009-Present
Associate Attending	Memorial Sloan Kettering Cancer Center New York, NY	03/01/2014-2017
Associate Member	Memorial Sloan Kettering Cancer Center New York, NY	03/01/2014-Present

3. Other Employment
N/A

E. EMPLOYMENT STATUS

Name of Employer: Weill Cornell Medical College, Cornell University
Employment Status: Full-time salaried by Weill Cornell Medical College, Cornell University

F. INSTITUTIONAL/HOSPITAL AFFILIATION

1. Primary Hospital Affiliation:	New York Presbyterian
2. Other Hospital Affiliations:	Memorial Sloan Kettering Hospital
3. Other Institutional Affiliations:	N/A

G. PERCENT EFFORT AND INSTITUTIONAL RESPONSIBILITIES

WCMC ANTICIPATED % EFFORT	(%)	Does the activity involve WCMC students/researchers? Yes
TEACHING	10%	Yes
CLINICAL	20%	Yes
ADMINISTRATIVE	10%	Yes
RESEARCH	60%	Yes
TOTAL	100%	

Research Activity / Key Contributions
Gastrointestinal (GI) and colorectal cancer (CRC) research has been a major focus of my research. One program that has successfully been clinical translated is the cloning and mechanistic characterization of *MutL Homologue 3 (MLH3). MLH3* is a DNA mismatch repair gene that is a Mendelian cause of increased germline colorectal cancer risk. Mechanistically, my lab also showed that functional redundancy between *MLH3* and another DNA mismatch repair gene *PMS2* resolved a long-standing paradox observed in clinical cancer genetics: why *MLH1* is a common cause of Lynch syndrome while *PMS2* and *MLH3* are less commonly mutated. Another highlight of my colorectal cancer research program that has successfully been clinically translated is writing the computational algorithm MAPP-MMR. MAPP-MMR is a computational tool that medical geneticists, genetic counselors and oncologists in North America, Europe, Japan and Australia use to diagnose Lynch syndrome missense variants as mutations or benign polymorphisms, and continuations of this work were published in *Nature Biotechnology* with commentaries on this work in *Nature* and *Nature Methods*. I have continued this line of investigation that I started several years before and worked to improve interpretation of human whole exome coding variants as mutations or benign polymorphisms. This work incorporates both structural and functional studies to improve variant interpretation, and has been published in several journals, including *Nature Biotechnology* with commentaries on this work in *Nature* and *Nature Methods*.

I have also continued a long term line of research into the mechanisms of colorectal cancer tumorigenesis and progression. This has provided new insights into the role of colorectal cancer initiating cells, Notch signaling, miR-34a, miR-23a, miR-1269, TGF-Beta and EGFR signaling in these mechanisms. In particular, we have developed novel experimental mouse models to study colorectal cancer progression, metastasis and chemoresistance, for which WCMC has filed US patents. This work has been published in *Journal of Clinical Investigation*, *Nature Biotechnology*, other journals and featured in the Biocentury biotechnology industry news publication SciBx and an associated patent.

For the past several years an important focus of my research has been genetic predisposition to Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma. My lab also has played important roles in the identification of several germline B cell malignancy predisposition genes, including (most recently) KDM1A, as well as PAX5, ETV6 ARID1A, USP45 and DIS3.

I am co-leading an international project under an NCI Cancer Moonshot and other grants to develop the first clinically tested cancer immunoprevention vaccine.

1. Administrative Activities (duties, dates): Describe administrative activities in the table below. To document administrative activities more extensively use a supplemental statement, refer to it here and attach it to the CV.

Administrative Activity	Date
Administrative duties	
Director, Adult and Cancer Genetics Clinic, UC Irvine Medical Center	2001-2009
Faculty, UC Irvine Genetic Counselor Masters Degree Training Program	2001-2009
Cancer Center Research American Cancer Society Seed Grant Review Committee	2002-2008
Organizer, Cancer Center Symposium, UCI "Human Genetic Variation: Merging Genetics with Clinical Medicine."	2003
UC Irvine Genetic Epidemiology Tenure Track Faculty Search Committee	2003
Genetic Epidemiology Research Institute Seminar and Annual Conference Organizer	2004-2008
Cancer Center Translational Research Grant Review Committee	2005-2008
Chair, Session, Novel Technologies in Cancer Research, UCI Cancer Center Annual Retreat.	2005
UC Irvine Hematology-Oncology Tenure Track Faculty Search Committee	2005
Search Committee for Chair, UCI Division of Medical Genetics	2005
UCI Institutional Biosafety Committee (IBC)	2005-2008
UCI School of Medicine Research Seed Grant Review Committee.	2006-2008
Executive Board, Genetic Epidemiology Research Institute, UC Irvine	2006-2008
Program in Pharmaceutical Sciences Tenure Track Faculty Search Committee	2006
Chair, GI Cancer Prevention Session at UCI Chao Family Comprehensive Cancer Center Chemoprevention Retreat	2006
Co-Chair**,** UCI Chao Family NCI Designated Comprehensive Cancer Center Program in Population Sciences	2007-2009
Director, Weill Cornell-NYPH Center for Advanced Digestive Care Colorectal Cancer Biobank	2009-2011
Faculty, NYPH/CUMC CME Review Courses for Gastroenterology	2009-2014
Interviewer, Applicants for Internal Medicine Residency Research Program Track	2009-2012

Faculty, WCMC Department of Medicine Annual Report Task Force	2011
Chair, search committees, NYPH CADC Genetic Counselor Recruitment	2011-2013
Member, Dept of Medicine Resident Research Award Selection Committee	2011-2012
Member, NYPH Oncology Strategic Plan-Personalized Medicine	2012-
Member, Department of Medicine Midcareer mentoring task force	2012-2013
Search Committee, Clinical and Research Directors NYPH/WCMC Department of Pediatrics Division of Medical Genetics	2014
Director, Center for Advanced Digestive Care Hereditary GI Cancer Registry and WCMC Neurosurgery Colloid Cyst Registries	2013
WCMC Cancer Center, Division of Oncology and Department of Medicine Faculty Recruitment	2013
Member, Department of Medicine Grand Rounds Speaker Selection Committee	2013-2014
Faculty, WCMC Oncology Board Review Course	2013-2014
Member, Search Committee WCMC Center for Metabolism	2014
WCMC/NYPH-ARCH Electronic Medical Record Research Data Repsitory (RDR) Scientific Advisory Board member	2014
WCMC Medical Student Teaching" Cancer Genetics"	2015
Member, American Society for Clinical Investigation (ASCI)	2015- Present
Member, American Association of Physicians (AAP)	2015- Present
Vice Chair for Basic and Translational Research, Department of Medicine.	2015
Director, Weill-Cornell Medicine Program in Mendelian Genetics	2015-Present
Co-Program Leader, Weill-Cornell Meyer Cancer Center Program in Genetics, Epigenetics and Systems Biology	2015-Present
Chair, WCM Genetics Faculty Initiative Committee	2016
Member, Cornell Ithaca Genome Biology Initiative Committee	2016
Co-Organizer, 2nd Department of Medicine Research Retreat	2017
Co-Director, Department of Medicine Research Fund for Future Program	2017
Co-Director, Department of Medicine Seed Grants Program	2017
Vice Chair for Research, Department of Medicine.	2018

EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

Activity / Responsibility	Dates
Scientific Advisory Board, Innovate Biopharmaceuticals (Nasdaq INNT)	2018-present
Member, US FDA Clinical and Molecular Genetics Panel	2007-2013 and 2019-2023
Scientific Advisory Board, Invitae Corporation (Nasdaq NVTA)	2012-2016
Scientific Advisory Board, Nanostring	2015-2016
Scientific Advisory Board, Acuamark	2015-2020
Peer Reviewer for journals New England Journal of Medicine, Nature Genetics, Nature Communications, Journal of the National Cancer Institute, Cell Stem Cell, Journal of Clinical Oncology, Cancer Research, Cancer Prevention Research, Gastroenterology, Oncogene, Human Molecular Genetics, Cancer Epidemiology, Biomarkers and Prevention, Human Mutation and others.	2004-Present
Member, American ASCO Cancer Education Coordinating Committee	2006-2008
Member, American Society for Clinical Oncology (ASCO) Scientific Program Committee	2006-2008

Member, NCI and Lance Armstrong Foundation Adolescent and Young Adult Oncology Program Review Group (PRG)	2006-2010
Advisory Board Member, NCI Colorectal Cancer Collaborative Family Registry Network (CCFR)	2007-2013
Ad hoc Grant Reviewer, NCI Study Section Cancer Epidemiology, Prevention and Control E	2007-2008
Ad hoc Grant Reviewer, Department of Defense CDRP Prostate Cancer Program	2007
Ad hoc Grant Reviewer ,SEP R01 and P01 RFA “Stem Cells and Cancer”	2008
Editorial Board, Cancer Prevention Research Journal	2008-2013
Present Chair, Correlative Sciences Committee, NCI DCP "A Phase IIa Randomized, Double-Blind Trial of Erlotinib in Inhibiting EGF Receptor Signaling in Aberrant Crypt Foci of the Colon"	2009-2013
Ad hoc Grant Reviewer, NCI GI SPORE Grants	2010
Ad hoc Grant Reviewer, Department of Defense IDEA Awards	2011
Member. PREVENT SEP, NCI Division of Cancer Prevention	2011-2013
Member, SEP Repeat Ad hoc NCI SBIR/STTR Cancer Diagnostics and Treatments (CDT)	2012-2013
Ad hoc Reviewer, NCI Provocative Questions Special Emphasis Panel	2012-2013
Ad hoc Grant Reviewer, DeGregorio Foundation	2012-2014
Reviewer Cancer UK	2012
Member, U54 NCI BETTRNet Barrett’s Esophagus Network Special Emphasis Panel	2012
Chair, Correlative Sciences Committee, NCI SWOG S8020 Phase III trial DFMO/Sulindac for Colon Adenoma and Second Promary Prevention Trial	2012-Present
Chair, Correlative Sciences Committee, NCI DCP Phase IIa trial "Naproxen for Lynch Syndrome Chemoprevention."	2013-Present
Member, -ASCO Cancer Prevention Committee CIGNA Taskforce ASCO President Cliff Hudis, ASCO Chief Medical Officer Richard Schilsky	2013
Member, ASCO Cancer Prevention Committee and Cancer Genetics sub-committee	2012-2013
Member, NCI R03 and R21 SEP Reviewer	2012-2013
Ad hoc Reviewer, member NCI Tumor Cell Biology (TCB) Study Section June 2013	2013
Ad hoc Grants Program Reviewer member, Commonwealth of Pennsylvania Grant Review	2013
Member, ASCO University Clinical Cancer Genetics Program Committee	2013-2014
Chartered Reviewer and Member, NCI Study Section “Cancer Etiology	2005-2010
Principal Investigator, Molecular Epidemiology of Non-Small Cell Lung Cancer (MENSCH) consortium.	2014-2016
Member, AACR Annual Meeting Program Committee	2015
Member, NCI Division of Cancer Prevention PREVENT Cancer Program External Advisory Board	2015
Chair, NCI R15 Tumor Cell Biology Study Section	2015
Member, Ad hoc reviewer, NCI Cancer Genetics Study Section	2015
Member, SEP Repeat Ad hoc NCI SBIR/STTR Cancer Diagnostics and Treatments (CDT)	2015
NCI Cancer Genetics Study Section ad hoc member	2016-2018

NCI Division of Cancer Prevention PREVENT Program External Advisory Board	2016-2017
NCI Tumor Cell Biology Study section ad hoc reviewer	2017
NCI Provocative Questions ad hoc reviewer	2017
Member, Tumor Cell Biology (TCB) Study Section	2018-2021

Selected Invited Lectures and Oral Presentations

University of Michigan Department of Medicine Grand Rounds "MLH3: A Novel Inherited Cause of atypical HNPCC"	2004
Hereditary Hematological Malignancies Conference, Creighton University, Omaha NE. "Genomic Technologies for Hereditary Colorectal Cancer and Acute Myeloid Leukemia Clustering."	2002
Chao Family NCI Designated Comprehensive Cancer Center Retreat, "Applied Genomic Technologies for Cancer Genetics." Palm Spring, CA	2002
Long Beach Veteran's Administration Hospital Department of Medicine Grand Rounds, "New Genes in Inherited Colorectal Cancer."	2003
California Cancer Registry Annual Conference "Sequence variation and Hereditary Colorectal Cancer."	2003
Harvard/Partners Center for Genetics and Genomics, Lecture series in Human Genetics"Inherited Colorectal Cancer: New Genes, Chips and SNPs	2004
Affymetrix Corporation Lecture series in human diseases "New Colorectal Cancer Susceptibility SNPs."Please list location	2004
National Cancer Control Center Technion Translational Cancer Prevention Workshop Haifa, Israel. "New causes of inherited colorectal cancer susceptibility	2004
Clalit Health Services International Educational Cancer Prevention Conference, Israel "Genetic Mechanisms in Clinical Cancer Genetics."	2004
MD Anderson Cancer Center, Blaffer Endowed Lecture, "Hypomorphic DNA Mismatch Repair Mutations."	2004
Albert Einstein College of Medicine, "Hypomorphic DNA Mismatch Repair Mutations."	2004
Deutsche Society for Gastroenterology (DGVS) Annual Meeting Koln, Germany "Novel Susceptibility Alleles and Prevention Strategies for Hereditary Colorectal Cancer." Keynote Address. Koln Germany.	2005
Annual Meeting International Collaborative Group on Inherited Colorectal Cancer of the Americas "Contribution of MSH6 Susceptibility Alleles to Hereditary Colorectal Cancer." (Session Chair) San Francisco	2005
NCI Division of Cancer Prevention Lecture series in translational medicine "HMGCR Inhibitors "Statins" and Colorectal Cancer Susceptibility: Pharmacogenetics for A Prospective Chemoprevention Trial." Bethesda, MD.	2005
American Society for Clinical Oncology (ASCO) Annual Meeting "Dissecting Risk Modifiers in Inherited Cancer Syndromes." (Chair of Session). Chicago, IL.	2006
Ohio State University, DNA Repair Seminar Series, "Hypomorphic MSI in Mlh3 Mutant Mice". Columbus Ohio.	2006

OSI Pharmaceuticals Lecture Series in Cancer Research "Molecular Cancer Prevention of IPMNs with Tarceva and IGF1R Inhibitors in Mismatch Repair Defective Colorectal Cancer. Boulder, Colorado	2006
American Society for Clinical Oncology (ASCO) Annual Meeting "New Developments in Hereditary Colorectal Cancer" Chicago, Illinois	2006
Western Pancreas Cancer Research Consortium Annual Conference "Molecular Cancer Prevention of IPMNs with Tarceva."	2006
Creighton University "Hypomorphic DNA Mismatch Repair and Single Molecule MSI" (Keynote address)	2006
PanCan Conference "Molecular Epidemiology of Pancreatic Cancer and Genetic Risk Factors" San Francisco, CA.	2006
American Society for Clinical Oncology (ASCO) Annual Meeting "New Developments in Hereditary Colorectal Cancer" (Session Chair) Chicago, IL	2006
AACR Frontiers in Cancer Prevention Conference "Molecular Cancer Prevention of IPMNs with Erlotinib." (Session Chair)	2007
Kaiser Clinical Oncology Symposium "Molecular Cancer Prevention" Los Angeles, CA.	2007
Stanford University Division of Clinical Cancer Genetics Seminar Series "Colorectal Cancer Risk Hypomorphs" Palo Alto, CA	2007
American Society for Clinical Oncology (ASCO) Annual Meeting "Genetic Testing in Diagnosis and Treatment of Hereditary Colorectal Cancer." (Session Chair) Chicago, IL	2007
Annual Meeting International Collaborative Group on Inherited Colorectal Cancer of the Americas Novel Molecular Diagnostics for Hereditary GI Cancer." (Session Chair). Dallas, TX.	2008
Albert Einstein College of Medicine Biomedical Sciences Lecture Series "NOTCH Signaling and Colon Cancer Initiating Cells."	2009
Hospital for Special Surgery Research Lecture Series "New molecular mechanisms and genes in Inflammatory Bowel disease associated colorectal cancer."	2009
New York Academy of Medicine "Hereditary GI Cancer Genetics." NCI Division of Cancer Prevention Conference "Erlotinib for chemoprevention of Pancreatic IPMNs."	2009
Creighton University Molecular Oncology Seminar Series. "Whole exome sequencing for cancer risk gene discovery."	2010
University of Connecticut Center for Genetics Lecture series "Colon cancer stem cells."	2010
Far Rockaway Hospital Research Lecture Series "GI Cancer Genetics for Generalists	2011
Cleveland Clinic Cancer Biology Seminar Series "Mechanisms of colon cancer metastasis."	2011
NY Academy of Sciences Cancer Metabolomics Symposium "DFMO for Colorectal Cancer Chemoprevention." (Panel with Craig Thompson)	2012
Champalimaud Foundation Annual Meeting on Tumor Metastasis Lisbon, Portugal. "CCR9 and progression of colorectal cancer."	2012
Scarsdale High School "Age of Exomes"	2012
Macao Polytechnic Institute (Macao) Distinguished Lecture Series "Exome analysis to identify cancer risk gene mutations"	2012

Guangzhou Third Oncology Hospital (China) Research Lecture Series "CCR9 prevents Colon Cancer Metastasis"	2012
Shenyang First Medical School "(China) Honored Biotechnology Seminar Series"CCR9 prevents Colon Cancer Metastasis	2012
Technion University Cancer Epidemiology Seminar Series (Israel) "Familial NSCLC Risk Gene Identification by Exome Sequencing	2013
Rockefeller University Center for Digestive Diseases Sciences Research Lecture Series "Role of miR-34a in Colon Cancer Stem Cell Asymmetric Division."	2013
Columbia University Department of Medicine, GI Division Grand Rounds "Parallels between Colorectal Cancer Chemoprevention and Chemotherapy: DFMO"	2013
Starr Cancer Consortium "Whole Exome and Genome Sequencing to Identify Novel Cancer Risk Genes."	2013
AACR Frontiers in Cancer Prevention Conference "Inhibition of EGFR Signaling in Colon ACFs by Erlotinib." Washington DC.	2013
Genetic Epidemiology of Leukemias Consortium Conference Salt Lake City, "Familial Myeloma and CLL."	2013
MD Anderson Cancer Center Division of Cancer Prevention Lecturer Seminar Series "DFMO and mechanisms of colorectal cancer chemoprevention	2014
Eugenides Foundation (Athens, Greece) Medical Oncology and Hematology Board Review Course, "Update in Clinical Cancer Genetics."	2015
UC Irvine "Age of Exomes: Identifying novel autoimmune and cancer susceptibility genes."	2015
City of Hope NCI Comprehensive Cancer Center "Identifying novel autoimmune and cancer susceptibility genes."	2015
AACR Annual Meeting "Chemokine-Targeted Mouse Models of Human Primary and Metastatic Colorectal Cancer."	2015
UCSD "Exome sequencing for Familial Crohn's Disease and Multiple Myeloma	2015
Creighton University Lynch Symposia "Genetics of Multiple Myeloma"	2015 Sept
Columbia University Precision Medicine Program "RP105 Mutations in Pediatric Crohn's Disease."	2016 May
INTERLYMPH conference "Mutation Burden Testing in Familial Multiple Myeloma" Rochester MN	2016 June
Genetics of Founder Populations International Conference "Whole Exome Sequencing Discovery of Familial Lung Cancer Risk Genes." Haifa, Israel	2016 July
New York Genome Center "Multiple Myeloma Predisposition Genes." New York, NY	2016 November
3rd New York Human Genetics Conference "Familial Multiple Myeloma"	2017 Jan 25th.
Co-organizer and host, 4th New York Human Genetics Conference (608 enrolled registrants)	2017 Sept 12
Participant, NCI Workshop "Mouse models of Immunotherapy and Immunorevention"	2017 Sept 19th
City of Hope Cancer Center "Genetics of Multiple Myeloma"	2017 Oct 2nd
Frontiers in Clinical Cancer Genetics "Genetics of Multiple Myeloma"	2018 April 19th
Cancer Moonshot Immunoprevention Workshop	2020 July 29

Translational Advances in Cancer Prevention Agent Development	2020 Aug 28th

H. PROFESSIONAL MEMBERSHIPS

Member/Officer/Fellow/Role	Organization	Dates
Member	Phi Beta Kappa	1986-Present
Member	Sigma Xi	1986-Present
Member	American Society for Human Genetics (ASHG)	1999-Present
Member	American Society for Clinical Oncology (ASCO)	2003-Present
Member	American Association for Cancer Research (AACR)	2003-Present
Fellow	American College of Medical Genetics (ACMG)	2013-Present
Fellow	American Society of Clinical Investigation (ASCI)	2015-Present

I. HONORS AND AWARDS

HONORS

2021-Co-Founder, AnaNeo Therapeutics
2018-Vice Chair for Research, Joan and Sanford Weill Department of Medicine, Weill-Cornell
2015-Present Fellow, American Society for Clinical Investigation (ASCI)
2015-Present Co-Program Leader, Genomics and Systems Biology, WCM Cancer Center
2015-Present Gladys and Roland Harriman Professor of Medicine and Genetic Medicine
2007-Present Member, US FDA Clinical and Molecular Genetics Panel
2009-Present, Director, Adult and Cancer Genetics Clinic, Weill Cornell Medical College
2013-Present Associate Member, Memorial Sloan Kettering Cancer Center
2012-2015 American Society for Clinical Oncology (ASCO) Cancer Prevention Committee
2006-2008 Chair, ASCO "Molecular Diagnostic Testing in Cancer"
2009-Present Associate Director of Research, Weill Cornell-New York Presbyterian Hospital Center for Advanced Digestive Care
2008-Present Editorial Board, *Cancer Prevention Research*
2006-2010 Chartered Reviewer, NCI Study Section "Cancer Etiology"
2006-2008-American Society for Clinical Oncology (ASCO) Scientific Program Committee
2005-Present Member, ASCO Cancer Education Coordinating Committee
2003-American Cancer Society Research Scholar
1986-1989, 1993-1995 NIH Medical Scientist Training Program
1986 *Summa cum laude*, Phi Beta Kappa, Princeton University

BIBLIOGRAPHY

1. Articles in professional peer-reviewed journals:

1. Glass, C.K., **Lipkin, S.M.**, Devary, O.V., and Rosenfeld, M.G. 1989. Positive and negative regulation of gene transcription by a retinoic acid-thyroid hormone receptor heterodimer. **Cell** 59:697-708.

2. **Lipkin, S.M.** 1990. An occupational hazard. **The Western Journal of Medicine** 153:565-566.

3. Naar, A.M., Boutin, J.M., **Lipkin, S.M**., Yu, V.C., Holloway, J.M., Glass, C.K., and Rosenfeld, M.G. 1991. The orientation and spacing of core DNA-binding motifs dictate selective transcriptional responses to three nuclear receptors. **Cell** 65:1267-1279.

4. **Lipkin, S.M.**, Nelson, C.A., Glass, C.K., and Rosenfeld, M.G. 1992. A negative retinoic acid response element in the rat oxytocin promoter restricts transcriptional stimulation by heterologous transactivation domains. **Proceedings of the National Academy of Sciences of the United States of America** 89:1209-1213.

5. **Lipkin, S.M.**, Naar, A.M., Kalla, K.A., Sack, R.A., and Rosenfeld, M.G. 1993. Identification of a novel zinc finger protein binding a conserved element critical for Pit-1-dependent growth hormone gene expression. **Genes & Development** 7:1674-1687.

6. **Lipkin, S.M.,** Grider, T.L., Heyman, R.A., Glass, C.K., and Gage, F.H. 1996. Constitutive retinoid receptors expressed from adenovirus vectors that specifically activate chromosomal target genes required for differentiation of promyelocytic leukemia and teratocarcinoma cells. **Journal of Virology** 70:7182-7189.

7. **Lipkin, S.M.**, Wang, V., Jacoby, R., Banerjee-Basu, S., Baxevanis, A.D., Lynch, H.T., Elliott, R.M., and Collins, F.S. 2000. MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability. **Nature Genetics** 24:27-35.

8. **Lipkin, S.M.**, Wang, V., Stoler, D.L., Anderson, G.R., Kirsch, I., Hadley, D., Lynch, H.T., and Collins, F.S. 2001. Germline and somatic mutation analyses in the DNA mismatch repair gene MLH3: Evidence for somatic mutation in colorectal cancers. **Human Mutation** 17:389-396.

9. Stella, A., Wagner, A., Shito, K., **Lipkin, S.M.**, Watson, P., Guanti, G., Lynch, H.T., Fodde, R., and Liu, B. 2001. A nonsense mutation in MLH1 causes exon skipping in three unrelated HNPCC families. **Cancer Research** 61:7020-7024.

10. **Lipkin, S.M**., Moens, P.B., Wang, V., Lenzi, M., Shanmugarajah, D., Gilgeous, A., Thomas, J., Cheng, J., Touchman, J.W., Green, E.D. and **Lipkin SM**. 2002. Meiotic arrest and aneuploidy in MLH3-deficient mice. **Nature Genetics** 31:385-390.

11. Lynch, H.T., Weisenburger, D.D., Quinn-Laquer, B., Snyder, C.L., Lynch, J.F., **Lipkin, S.M**., and Sanger, W.G. 2002. Family with acute myelocytic leukemia, breast, ovarian, and gastrointestinal cancer. **Cancer Genetics and Cytogenetics** 137:8-14.

12. Kudryavtseva, E.I., Sugihara, T.M., Wang, N., Lasso, R.J., Gudnason, J.F., **Lipkin, S.M.,** and Andersen, B. 2003. Identification and characterization of Grainyhead-like epithelial transactivator (GET-1), a novel mammalian Grainyhead-like factor. **Developmental Dynamics** 226:604-617.

13. **Lipkin SM**, Rozek LS, Rennert G, Yang W, Chen PC, Hacia J, Hunt N, Shin B, Fodor S, Kokoris M, Greenson JK, Fearon E, Lynch H, Collins F, Gruber SB. 2004. The MLH1 D132H

variant is associated with susceptibility to sporadic colorectal cancer. **Nature Genetics** 36(7): 694-9.

14. Cannavo, E., Marra, G., Sabates-Bellver, J., Menigatti, M., **Lipkin, S.M.**, Fischer, F., Cejka, P., and Jiricny, J. 2005. Expression of the MutL homologue hMLH3 in human cells and its role in DNA mismatch repair. **Cancer Research** 65:10759-10766.

15. Chen, P.C., Dudley, S., Hagen, W., Dizon, D., Paxton, L., Reichow, D., Yoon, S.R., Yang, K., Arnheim, N., Liskay, R.M., and **Lipkin SM**. 2005. Contributions by MutL homologues Mlh3 and Pms2 to DNA mismatch repair and tumor suppression in the mouse. **Cancer Research** 65:8662-8670.

16. Frank, S.A., Chen, P.C., and **Lipkin, S.M**. 2005. Kinetics of cancer: a method to test hypotheses of genetic causation. **BMC Cancer** 5:163.

17. Kolas, N.K., Svetlanov, A., Lenzi, M.L., Macaluso, F.P., **Lipkin, S.M.**, Liskay, R.M., Greally, J., Edelmann, W., and Cohen, P.E. 2005. Localization of MMR proteins on meiotic chromosomes in mice indicates distinct functions during prophase I. **Journal of Cell Biology** 171:447-458.

18. Rozek, L.S., **Lipkin, S.M.**, Fearon, E.R., Hanash, S., Giordano, T.J., Greenson, J.K., Kuick, R., Misek, D.E., Taylor, J.M., Douglas, J.A., et al. 2005. CDX2 polymorphisms, RNA expression, and risk of colorectal cancer. **Cancer Research** 65:5488-5492.

19. Shin, B.Y., Chen, H., Rozek, L.S., Paxton, L., Peel, D.J., Anton-Culver, H., Rennert, G., Mutch, D.G., Goodfellow, P.J., Gruber, S.B., and **Lipkin SM**. 2005. Low allele frequency of MLH1 D132H in American colorectal and endometrial cancer patients. **Diseases of the Colon and Rectum** 48:1723-1727.

20. Chao, E.C., and **Lipkin, S.M.** 2006. Molecular models for the tissue specificity of DNA mismatch repair-deficient carcinogenesis. **Nucleic Acids Research** 34:840-852.

21. Wu, X., Tsai, C.Y., Patam, M.B., Zan, H., Chen, J.P., **Lipkin, S.M.**, and Casali, P. 2006. A role for the MutL mismatch repair Mlh3 protein in immunoglobulin class switch DNA recombination and somatic hypermutation. **Journal of Immunology** 176:5426-5437.

22. Zell, J.A., Rhee, J.M., Ziogas, A., **Lipkin, S.M.**, and Anton-Culver, H. 2007. Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California. **Cancer Epidemiology, Biomarkers & Prevention** 16:546-552.

23. Chao, E.C., Velasquez, J.L., Witherspoon, M.S., Rozek, L.S., Peel, D., Ng, P., Gruber, S.B., Watson, P., Rennert, G., Anton-Culver, H., and **Lipkin SM**. 2008. Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR). **Human Mutation** 29:852-860.

24. Chen, P.C., Kuraguchi, M., Velasquez, J., Wang, Y., Yang, K., Edwards, R., Gillen, D., Edelmann, W., Kucherlapati, R., and **Lipkin, S.M.** Novel roles for MLH3 deficiency and TLE6-like amplification in DNA mismatch repair-deficient gastrointestinal tumorigenesis and progression. **PLoS Genetics** 2008 4:e1000092.

25. Le, H., Ziogas, A., **Lipkin, S.M.**, and Zell, J.A. 2008. Effects of socioeconomic status and treatment disparities in colorectal cancer survival. **Cancer Epidemiology, Biomarkers & Prevention** 17:1950-1962.

26. Le, H., Ziogas, A., Rhee, J.M., Lee, J.G., **Lipkin, S.M.**, and Zell, J.A. 2008. A population-based, descriptive analysis of malignant intraductal papillary mucinous neoplasms of the pancreas. **Cancer Epidemiology, Biomarkers & Prevention** 17:2737-2741.

27. Pan, Z., Sikandar, S., Witherspoon, M., Dizon, D., Nguyen, T., Benirschke, K., Wiley, C., Vrana, P., and **Lipkin, S.M**. 2008. Impaired placental trophoblast lineage differentiation in Alkbh1(-/-) mice. **Developmental Dynamics** 237:316-327.

28. Edwards, R.A., Witherspoon, M., Wang, K., Afrasiabi, K., Pham, T., Birnbaumer, L., and **Lipkin, S.M.** 2009. Epigenetic repression of DNA mismatch repair by inflammation and hypoxia in inflammatory bowel disease-associated colorectal cancer. **Cancer Research** 69:6423-6429.

29. Le, H., Ziogas, A., Taylor, T.H., **Lipkin, S.M.**, and Zell, J.A. 2009. Survival of distinct Asian groups among colorectal cancer cases in California. **Cancer** 115:259-270.

30. Herbert, B.S., Chanoux, R.A., Liu, Y., Baenziger, P.H., Goswami, C.P., McClintick, J.N., Edenberg, H.J., Pennington, R.E., **Lipkin, S.M.**, and Kopelovich, L. 2010. A molecular signature of normal breast epithelial and stromal cells from Li-Fraumeni syndrome mutation carriers. **Oncotarget** 1:405-422.

31. **Lipkin, S.M**., Chao, E.C., Moreno, V., Rozek, L.S., Rennert, H., Pinchev, M., Dizon, D., Rennert, G., Kopelovich, L., and Gruber, S.B. 2010. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. **Cancer Prevention Research** 3:597-603.

32. Sikandar, S., Dizon, D., Shen, X., Li, Z., Besterman, J., and **Lipkin, S.M**. 2010. The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. **Oncotarget** 1:596-605.

33. Sikandar, S.S., Pate, K.T., Anderson, S., Dizon, D., Edwards, R.A., Waterman, M.L., and **Lipkin, S.M**. 2010. NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. **Cancer Research** 70:1469-1478.

34. Zhao, F., Edwards, R., Dizon, D., Afrasiabi, K., Mastroianni, J.R., Geyfman, M., Ouellette, A.J., Andersen, B., and **Lipkin, S.M.** 2010. Disruption of Paneth and goblet cell homeostasis and increased endoplasmic reticulum stress in Agr2-/- mice. **Developmental Biology** 338:270-279.

35. Shin, Y.J., Hencey, B., **Lipkin, S.M.**, and Shen, X. 2011. Frequency domain analysis reveals external periodic fluctuations can generate sustained p53 oscillation. **PloS One** 6:e22852.

36. Benoit, Y.D., Laursen, K.B., Witherspoon, M.S., **Lipkin, S.M**., and Gudas, L.J. Inhibition of PRC2 histone methyltransferase activity increases TRAIL-mediated apoptosis sensitivity in human colon cancer cells. **J Cell Physiol** 2013 Apr 228(4): 764-72.

37. Chen, H.J., Edwards, R., Tucci, S., Bu, P., Milsom, J., Lee, S., Edelmann, W., Gumus, Z.H., Shen, X., and **Lipkin, S**. 2012. Chemokine 25-induced signaling suppresses colon cancer invasion and metastasis. **Journal of Clinical Investigation** 122:3184-3196. *A Commentary on this paper was featured in the BioCentury journal SciBX 5:32 (2012). It also resulted in a patent filed by WCMC that is in process of being licensed.*

38. Crous-Bou, M., Rennert, G., Salazar, R., Rodriguez-Moranta, F., Rennert, H.S., Lejbkowicz, F., Kopelovich, L., **Lipkin, S.M**., Gruber, S.B., and Moreno, V. 2012. Genetic polymorphisms in fatty acid metabolism genes and colorectal cancer. **Mutagenesis** 27:169-176.

39. Jahid, S., Sun, J., Edwards, R.A., Dizon, D., Panarelli, N.C., Milsom, J.W., Sikandar, S.S., Gumus, Z.H., and **Lipkin, S.M**. 2012. miR-23a promotes the transition from indolent to invasive colorectal cancer. **Cancer Discovery** 2:540-553.

40. Stadler ZK, Esposito D, Shah S, Vijai J, Yamrom B, Levy D, Lee YH, Kendall J, Leotta A, Ronemus M, Hansen N, Sarrel K, Rau-Murthy R, Schrader K, Kauff N, Klein RJ, **Lipkin SM**, Murali R, Robson M, Sheinfeld J, Feldman D, Bosl G, Norton L, Wigler M, Offit K. 2012. Rare de novo germline copy-number variation in testicular cancer. **American Journal of Human Genetics** 91:379-383.

41. Verma, S., Salmans, M.L., Geyfman, M., Wang, H., Yu, Z., Lu, Z., Zhao, F., **Lipkin, S.M**., and Andersen, B. 2012. The estrogen-responsive Agr2 gene regulates mammary epithelial proliferation and facilitates lobuloalveolar development. **Developmental Biology** 369:249-260.

42. Wang, X., Wei, X., Thijssen, B., Das, J., **Lipkin, S.M**., and Yu, H. 2012. Three-dimensional reconstruction of protein networks provides insight into human genetic disease. **Nature Biotechnology** 30:159-164. *The journal Nature published a "Technology Feature" commentary that highlighted this paper. Additionally, the journal Nature Methods dedicated its Systems Biology commentary section in "Research Highlights" to solely feature this paper.*

43. Vijai, J., Kirchhoff, T., Schrader, K.A., Brown, J., Dutra-Clarke, A.V., Manschreck, C., Hansen, N., Rau-Murthy, R., Sarrel, K., Przybylo, J., Shah, S., Cheguri, S., Stadler, Z., Zhang, L., Paltiel, O., Ben-Yehuda, D., Viale, A., Portlock, C., Straus, D., **Lipkin, SM**, Lacher, M., Robson, M., Klein, R.J., Zelenetz, A. & Offit, K. Susceptibility Loci associated with specific and shared subtypes of lymphoid malignancies. **PLoS Genetics** 2013 9(1):e1003220 (2013).

44. Bu, P., Chen, K., Chen, J., Wang, L., Walters, J., Shin, Y., Goerger, J, Sun, J., Witherspoon, M., Rakhilin, N., Li, J., Yang, H., Milsom, J., Lee, S., Zipfel, W., Jin, M., Gümüş, G., **Lipkin*, S**., and Shen, X. A microRNA miR-34a Regulated Bimodal Switch targets Notch in Colon Cancer Stem Cells. **Cell Stem Cell** 2013 May 2;12(5):602-15 (*Co-corresponding author).

The journal Cell Stem Cell published a Preview describing this work in the same issue on pages 499-500.

45. Guo Y, Wei X, Das J, Grimson A, **Lipkin SM**, Clark AG, Yu H. Dissecting Disease Inheritance Modes in a Three-Dimensional Protein Network Challenges the "Guilt-by-Association" Principle. **American Journal of Human Genetics**. 2013 Jul 11;93(1):78-89.

46. Das J, Vo TV, Wei X, Mellor JC, Tong V, Degatano AG, Wang X, Wang L, Cordero NA, Kruer-Zerhusen N, Matsuyama A, Pleiss JA, **Lipkin SM**, Yoshida M, Roth FP, Yu H. Cross-species protein interactome mapping reveals species-specific wiring of stress response pathways. **Science Signaling**. 2013 May 21;6(276):ra38.

47. Witherspoon M, Chen Q, Kopelovich L, Gross SS, **Lipkin SM**. Unbiased metabolite profiling indicates that a diminished thymidine pools is the underlying mechanism of colon cancer chemoprevention by alpha-difluoro-methylornithine (DFMO).**Cancer Discovery** 2013 Sep;3 (9):1072-81. *A Commentary in the same issue of the journal highlighted this work.*

48. Vijai J, Kirchhoff T, Schrader KA, Brown J, Dutra-Clarke AV, Manschreck C, Hansen N, Rau-Murthy R, Sarrel K, Przybylo J, Shah S, Cheguri S, Stadler Z, Zhang L, Paltiel O, Ben-Yehuda D, Viale A, Portlock C, Straus D, **Lipkin SM**, Lacher M, Robson M, Klein RJ, Zelenetz A, Offit. Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies. **PLoS Genet**. 2013;9(1):e1003220.

49. Ekta Khurana, Yao Fu, Vincenza Colonna, Xinmeng Jasmine Mu, Hyun Min Kang, Tuuli Lappalainen, Andrea Sboner, Lucas Lochovsky, Jieming Chen, Arif Harmanci, Jishnu Das, Alexej Abyzov, Suganthi Balasubramanian, Kathryn Beal, Dimple Chakravarty, Daniel Challis, Yuan Chen, Declan Clarke, Laura Clarke, Fiona Cunningham, Uday S. Evani, Paul Flicek, Robert Fragoza, Erik Garrison, Richard Gibbs, Zeynep H. Gümüş, Javier Herrero, Naoki Kitabayashi, Yong Kong, Kasper Lage, Vaja Liluashvili, **Steven Lipkin**, Daniel G. MacArthur, Gabor Marth, Donna Muzny, Tune H. Pers, Graham R. S. Ritchie, Jeffrey A. Rosenfeld, Cristina Sisu, Xiaomu Wei, Michael Wilson, Yali Xue, Fuli Yu, 1000 Genomes Project Consortium, Emmanouil T. Dermitzakis, Haiyuan Yu, Mark A. Rubin, Chris Tyler-Smith and Mark Gerstein “Integrative annotation of variants from 1,092 humans: application to cancer genomics” **Science**. 2013 Oct 4;342(6154):1235587.

50. Marta Crous-Bou, Gad Rennert, Daniel Cuadras, Ramon Salazar, David Cordero, Hedy Saltz Rennert, Flavio Lejbkowicz, Levy Kopelovich, **Steven M Lipkin**, Stephen B Gruber and Victor Moreno. Polymorphisms in alcohol metabolism genes ADH1B and ALDH2, alcohol consumption and colorectal cancer **PloSOne** 2013 Nov 25;8(11):e80158.

51. Xiaomu Wei, Jishnu Das, Robert Fragoza, Jin Liang, Francisco M. Bastos de Oliveira, Hao Ran Lee, Xiujuan Wang, Matthew Mort, Peter D. Stenson, David N. Cooper, **Steven M. Lipkin**, Marcus B. Smolka, Haiyuan Yu. A massively parallel pipeline to clone DNA variants and examine molecular phenotypes of human disease mutations. PloS Genetics 2014 Dec 11;10(12):e1004819.

52. Gillen, DG, Meyskens, FL, Morgan, TM, Zell, J, Carroll, R., Benya, R.,Chen, WP,Mo, A., Tucker,C., Bhattacharya, A.,Huang, Z.,Arcilla, M.,Wong, V.,Chung,V., Gonzalez,R.,

Rodriguez,L., Szabo, E., Rosenberg, D and **Lipkin, SM.** A Phase IIa Randomized, Double-Blind Trial of Erlotinib in Inhibiting EGF Receptor Signaling in Aberrant Crypt Foci of the Colorectum. **Cancer Prevention Research** 2015 Mar;8(3):222-30.

53. Bu, P., Wang, L., Chen, K., Rakhilin, N., Sun, J., Closa, A., Tung, K., King, S., Varanko, A., Xu, Y., Chen, J., Zessin, A., Shealy, J., Cummings, B., Hsu, D., **Lipkin, SM**, Moreno, V., Gümüş, Z., and Shen, X. miR-1269 Promotes Metastasis and Forms a .Positive Feedback Loop with TGF-Beta. **Nature Communications** 2015 Apr 15;6:6879. PMID: 25872451.

54. Chen, H., Sun, J., Huang, Z., Hou, H., Arcilla, M, Rakhilin, N., Joe, D., Choi, J., Gadamsetty, P., Milsom, J., Nandakumar, G., Longman, R., Zhou, K., Edwards, R., Chen, J., Chen, K., Bu, P. Miller, A., Gümüş, Z., Shuler, M., Nishimura, N., Edelmann, W., Shen, X., **Lipkin, SM**. Chemokine-Targeted Mouse Models of Human Primary and Metastatic Colorectal Cancer. **Nature Biotechnology** 2015 Jun;33(6):656-60. PMID: 26006007.

55. Goodenberger ML, Thomas BC, Riegert-Johnson D, Boland CR, Plon SE, Clendenning M, Win AK, Senter L, **Lipkin SM**, Stadler ZK, Macrae FA, Lynch HT, Weitzel JN, de la Chapelle A, Syngal S, Lynch P, Parry S, Jenkins MA, Gallinger S, Holter S, Aronson M, Newcomb PA, Burnett T, Le Marchand L, Pichurin P, Hampel H, Terdiman JP, Lu KH, Thibodeau S, Lindor NM. PMS2 monoallelic mutation carriers: the known unknown. Genetic Medicine 2016 Jan;18(1):13-9. PMID: 25856668.

56. Topka S, Vijai J, Walsh MF, Jacobs L, Maria A, Villano D, Gaddam P, Wu G, McGee RB, Quinn E, Inaba H, Hartford C, Pui CH, Pappo A, Edmonson M, Zhang MY, Stepensky P, Steinherz P, Schrader K, Lincoln A, Bussel J, **Lipkin SM**, Goldgur Y, Harit M, Stadler ZK, Mullighan C, Weintraub M, Shimamura A, Zhang J, Downing JR, Nichols KE, Offit K. Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia. **PLoS Genetics** 2015 Jun 23;11(6):e1005262. PMID: 26102509.

57. Robson ME, Bradbury AR, Arun B, Domchek SM, Ford JM, Hampel HL**, Lipkin SM**, Syngal S, Wollins DS, Lindor NM. J Clin Oncol. 2015 Aug 31. "American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility." **Journal of Clinical Oncology** 2015 Nov 1;33(31):3660-7. PMID: 26324357

58. Bu P, Wang L, Chen KY, Srinivasan T, Murthy PK, Tung KL, Varanko AK, Chen HJ, Ai Y, King S, **Lipkin SM**, Shen X. A miR-34a-Numb Feedforward Loop Triggered by Inflammation Regulates Asymmetric Stem Cell Division in Intestine and Colon Cancer. **Cell Stem Cell** 2016 Feb 4;18(2):189-202. PMID: 26849305.

59. Lihua Wang Pengcheng Bu Yiwei Ai Tara Srinivasan Huanhuan Joyce Chen Kun Xiang **Steven M Lipkin** Xiling Shen. A long non-coding RNA targets microRNA miR-34a to regulate colon cancer stem cell asymmetric division. **eLife** 2016;10.7554/eLife.14620.

60. Tara Srinivasan, Jewell Walters, Pengcheng Bu, Elaine Bich Than, Kuei-Ling Tung, Kai-Yuan Chen, Nicole Panarelli, Jeff Milsom, Leonard Augenlicht, **Steven M. Lipkin***, and Xiling Shen*. NOTCH Signaling Regulates Asymmetric Cell Fate of Fast- and Slow-Cycling Colon Cancer-Initiating Cells. **Cancer Research**. Cancer Res. 2016 Jun 1;76(11):3411-21. PMID: 27197180. (*Co-corresponding author).

61. Srinivasan T, Than EB, Bu P, Tung KL, Chen KY, Augenlicht L, **Lipkin SM*,** Shen X*. Notch signalling regulates asymmetric division and inter-conversion between lgr5 and bmi1 expressing intestinal stem cells. **Scientific Reports** 2016 May 16;6:26069. PMID: 27181744. (*Co-corresponding author).

62. Schrader KA, Stratton KL, Murali R, Laitman Y, Cavallone L, Offit L, Wen YH, Thomas T, Shah S, Rau-Murthy R, Manschreck C, Salo-Mullen E, Otegbeye E, Corines M, Zhang L, Norton L, Hudis C, Klein RJ, Kauff ND, Robson M, Stadler ZK, Haber DA, **Lipkin SM**, Friedman E, Foulkes WD, Altshuler D, Vijai J, Offit K. Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant**. Journal of Clinical Oncology** 2016 Mar 10;34(8):e61-7. PMID: 24982446

63. Chen HJ, Wei Z, Sun J, Bhattacharya A, Savage DJ, Serda R, Mackeyev Y, Curley SA, Bu P, Wang L, Chen S, Cohen-Gould L, Huang E, Shen X, **Lipkin SM**, Copeland NG, Jenkins NA, Shuler ML. A recellularized human colon model identifies cancer driver genes. **Nature Biotechnology** 2016 Aug;34(8):845-51. doi: 10.1038/nbt.3586. Epub 2016 Jul 11. PMID: 27398792

64. Joseph Vijai, Sabine Topka, Vignesh Ravichandran, Danylo Villano, Tinu Thomas, Ann Maria, Pragna Gaddam, Anne Lincoln, Kara Maxwell, Kasmintan Schrader, Steven Hart, **Steven Lipkin**, Susan Neuhausen, Michael Walsh, Liying Zhang, Zsofia Stadler, Mark Robson, Jeffrey Weitzel, Mark Daly, Katherine Nathanson, Fergus Couch, Larry Norton, Gadi Rennert and Kenneth Offit. A recurrent ERCC3 truncating mutation confers moderate risk for breast cancer. **Cancer Discovery** 2016 Nov;6 (11):1267-1275. PMID: 27655433

65. Jahid S, Sun J, Gelincik O, Blecua P, Edelmann W, Kucherlapati R, Zhou K, Jasin M, Gümüş ZH, Li**pkin SM.** Inhibition of colorectal cancer genomic copy number alterations and chromosomal fragile site tumor suppressor FHIT and WWOX deletions by DNA mismatch repair. **Oncotarget**. 2017 May 10. PMID: 28548965

66. Chen KY, Srinivasan T, Tung KL, Belmonte JM, Wang L, Murthy PKL, Choi J, Rakhilin N, King S, Varanko AK, Witherspoon M, Nishimura N, Glazier JA, **Lipkin SM**, Bu P, Shen X.

67. Crespo M, Vilar E, Tsai SY, Chang K, Amin S, Srinivasan T, Zhang T, Pipalia NH, Chen HJ, Witherspoon M, Gordillo M, Xiang JZ, Maxfield FR, **Lipkin S**, Evans T, Chen S. Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing. **Nature Medicine** 2017 Jul;23(7):878-884

68. Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, Pradhan N, Arnold A, Walsh MF, Li Y, Balakrishnan AR, Syed A, Prasad M, Nafa K, Carlo MI, Cadoo KA, Sheehan M, Fleischut MH, Salo-Mullen E, Trottier M, **Lipkin SM**, Lincoln A, Mukherjee S, Ravichandran V, Cambria R, Galle J, Abida W, Arcila ME, Benayed R, Shah R, Yu K, Bajorin DF, Coleman JA, Leach SD, Lowery MA, Garcia-Aguilar J, Kantoff PW, Sawyers CL, Dickler MN, Saltz L, Motzer RJ, O'Reilly EM, Scher HI, Baselga J, Klimstra DS, Solit DB, Hyman DM, Berger MF, Ladanyi M, Robson ME, Offit K. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. **JAMA**. 2017 Sep 5;318(9):825-835.

69. Waller RG, Darlington TM, Wei X, Madsen MJ, Thomas A, Curtin K, Coon H, Rajamanickam V, Musinsky J, Jayabalan D, Atanackovic D, Rajkumar SV, Kumar S, Slager S, Middha M, Galia P, Demangel D, Salama M, Joseph V, McKay J, Offit K, Klein RJ, **Lipkin SM**, Dumontet C, Vachon CM, Camp NJ. Novel pedigree analysis implicates DNA repair

and chromatin remodeling in multiple myeloma risk. **PLoS Genet**. 2018 Feb 1;14(2):e1007111

70. Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V, Snyder C, Vachon CM, McKay JD, Wang SP, Jayabalan DS, Jacobs LM, Becirovic D, Waller RG, Artomov M, Viale A, Patel J, Phillip JM, Chen-Kiang S, Curtin K, Salama M, Atanackovic D, Niesvizky R, Landgren O, Slager SL, Godley LA, Churpek J, Garber JE, Anderson KC, Daly MJ, Roeder RG, Dumontet C, Lynch HT, Mullighan CG, Camp NJ, Offit K, Klein RJ, Yu H, Cerchietti L, **Lipkin SM**. Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma. **Cancer Res.** 2018 Mar 20.
71. Lencz T, Yu J, Palmer C, Carmi S, Ben-Avraham D, Barzilai N, Bressman S, Darvasi A, Cho JH, Clark LN, Gümüş ZH, Jos Liu J, Hsieh CL, Gelincik O, Devolder B, Sei S, Zhang S, Lipkin SM, Chang YF. Joseph V, Klein R, Lipkin S, Offit K, Ostrer H, Ozelius LJ, Peter I, Atzmon G, Pe'er I. High-depth whole genome sequencing of an Ashkenazi Jewish reference panel: enhancing sensitivity, accuracy, and imputation. **Hum Genet. 2018 Apr**; 137(4):343-355. PMID: 29705978.
72. Choi J, Rakhilin N, Gadamsetty P, Joe DJ, Tabrizian T, Lipkin SM, Huffman DM, Shen X, Nishimura N. Intestinal crypts recover rapidly from focal damage with coordinated motion of stem cells that is impaired by aging. **Sci Rep.** 2018 Jul 20;8(1):10989 PMID: 30030455.

73. Ravichandran V, Shameer Z, Kemel Y, Walsh M, Cadoo K, **Lipkin S**, Mandelker D, Zhang L, Stadler Z, Robson M, Offit K, Vijai J. Toward automation of germline variant curation in clinical cancer genetics. **Genet Med**. 2019 Feb 21. PMID: 30787465.

74. Artomov M, Joseph V, Tiao G, Thomas T, Schrader K, Klein RJ, Kiezun A, Gupta N, Margolin L, Stratigos AJ, Kim I, Shannon K, Ellisen LW, Haber D, Getz G, Tsao H, **Lipkin SM**, Altshuler D, Offit K, Daly MJ. Case-control analysis identifies shared properties of rare germline variation in cancer predisposing genes. **Eur J Hum Genet.** 2019 Feb 4. PMID:30718883.

75. Glynn S, **Lipkin S**, Zhang T, Sboner A, Elemento O, Van Besien K, Beltran H. The application of precision medicine in diagnosing familial Mediterranean fever. **Leuk Lymphoma.** 2019 Jan 30:1-3. PMID: 30698071.

76. Liu J, Hsieh CL, Gelincik O, Devolder B, Sei S, Zhang S, **Lipkin SM**, Chang YF. Proteomic characterization of outer membrane vesicles from gut mucosa-derived fusobacterium nucleatum. **J Proteomics.** PMID 30634002

77. Chen KY, Srinivasan T, Lin C, Tung KL, Gao Z, Hsu DS, **Lipkin SM**, Shen X. Single-Cell Transcriptomics Reveals Heterogeneity and Drug Response of Human Colorectal Cancer Organoids. **Conf Proc IEEE Eng Med Biol Soc.** 2018 Jul;2018:2378-2381. PMID: 30440885.

78. Pertesi M, Vallée M, Wei X, Revuelta MV…**Lipkin SM**, McKay JD, Dumontet C. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. **Leukemia** 2019 Apr 9. PMID: 30967618.

79. Ravichandran V, Shameer Z, Kemel Y, Walsh M, Cadoo K, **Lipkin S**, Mandelker D, Zhang L, Stadler Z, Robson M, Offit K, Vijai J. Toward automation of germline variant curation in clinical cancer genetics. **Genet Med. 2019 Feb 21.** PMID: 30787465.

80. Artomov M, Joseph V, Tiao G, Thomas T, Schrader K, Klein RJ, Kiezun A, Gupta N, Margolin L, Stratigos AJ, Kim I, Shannon K, Ellisen LW, Haber D, Getz G, Tsao H, **Lipkin SM**, Altshuler D, Offit K, Daly MJ.**Eur J Hum Genet. 2019 May;27(5):824-828.**

81. Witherspoon M, Sandu D, Lu C, Wang K, Edwards R, Yeung A, Gelincik O, Manfredi G, Gross S, Kopelovich L, **Lipkin SM**. ETHE1 overexpression promotes SIRT1 and PGC1α mediated aerobic glycolysis, oxidative phosphorylation, mitochondrial biogenesis and colorectal cancer. Oncotarget. 2019 Jun 18;10(40):4004-4017. 2019 Jun 18. PMID: 31258845.

82. Willis JA, Reyes-Uribe L, Chang K, **Lipkin SM**, Vilar E. Immune Activation in Mismatch Repair Deficient Carcinogenesis: More Than Just Mutational Rate. Clin Cancer Res. 2019 Aug 5. PMID: 31383734

83. Huang SH, McCann CD, Mota TM, Wang C, **Lipkin SM**, Jones RB. Have Cells Harboring the HIV Reservoir Been Immunoedited? **Front Immunol.** 2019 Aug 6;10:1842. 2019 PMID: 31447850

84. Offit K, Tkachuk KA, Stadler ZK, Walsh MF, Diaz-Zabala H, Levin JD, Steinsnyder Z, Ravichandran V, Sharaf RN, Frey MK, **Lipkin SM**, Robson ME, Hamilton JG, Vijai J, Mukherjee S.J Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening. **Journal of Clin Oncology** 2020 Jan 10 PMID: 31922925

85. Frey MK, Kahn RM, Chapman-Davis E, Tubito F, Pires M, Christos P, Anderson S, Mukherjee S, Jordan B, Blank SV, Caputo TA, Sharaf RN, Offit K, Holcomb K, Lipkin S. Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling. **Journal of Clin Oncology** 2020 Jan 10 PMID: 31922918.

86. Annapragada A, Sikora A, Bollard C, Conejo-Garcia J, Cruz CR, Demehri S, Demetriou M, Demirdjian L, Fong L, Horowitz M, Hutson A, Kadash-Edmondson K, Kufe D, **Lipkin S**, Liu S, McCarthy C, Morgan M, Morris Z, Pan Y, Pasquini M, Schoenberger S, Van Allen E, Vilar E, Xing Y, Zha W; IOTN Consortium, Odunsi A. Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer. **J Immunother Cancer.** 2020 Jun;8(1):e000796. PMID: 32554617.

87. Reyes-Uribe L, Wu W, Gelincik O, Bommi PV, Francisco-Cruz A, Solis LM, Lynch PM, Lim R, Stoffel EM, Kanth P, Samadder NJ, Mork ME, Taggart MW, Milne GL, Marnett LJ, Vornik L, Liu DD, Revuelta M, Chang K, You YN, Kopelovich L, Wistuba II, Lee JJ, Sei S, Shoemaker RH, Szabo E, Richmond E, Umar A, Perloff M, Brown PH, **Lipkin SM***, Vilar E*. **Gut.** 2020 Jul 8:gutjnl-2020-320946. PMID: 32641470. *Co-corresponding author.

88. Selvan, M., Zauderer, M. Rudin, Jones, S., C. Mukherjee, S., Offit, K., Onel, K., Rennert, G., Velculescu, V., **Lipkin, SM**, Klein, RJ, and Gümüş, Z., Inherited rare, deleterious variants in ATM increase lung adenocarcinoma risk. **J. Thoracic Oncology** 2020.

DOI:https://doi.org/10.1016/j.jtho.2020.08.017.

89. Palikuqi, B., Nguyen, D., Li, G., Schreiner, R., Pellegata, A., Liu, Y., Redmond, D., Geng, F., Lin, Y., Gómez-Salinero, J., Yokoyama, M., Zumbo, P, Zhang, T., Kunar, B., Witherspoon, M., Han T., Tedeschi, A., Scottoni, F., **Lipkin, SM**, Dow, L., Elemento, O, Xiang, J., Shido, K., Spence, J., Zhou, Q., Schwartz, R., De Coppi, P., Rabbany,S., and Rafii, S., Adaptable haemodynamic endothelial cells for organogenesis and tumorigenesis. **Nature** 2020. https://doi.org/10.1038/s41586-020-2712-z.

90. Topka S, Steinsnyder Z, Ravichandran V, Tkachuk K, Kemel Y, Bandlamudi C, Winkel Madsen M, Furberg H, Ouerfelli O, Rudin CM, Iyer G, **Lipkin SM**, Mukherjee S, Solit DB, Berger MF, Bajorin DF, Rosenberg JE, Taylor BS, de Stanchina E, Vijai J, Offit K. Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. **Clin Cancer Res**. 2020 Nov 16. doi: 10.1158/1078-0432.CCR-20-3322.

91. Dohlman AB, Arguijo Mendoza D, Ding S, Gao M, Dressman H, Iliev ID, **Lipkin SM**, Shen X. The cancer microbiome atlas: a pan-cancer comparative analysis to distinguish tissue-resident microbiota from contaminants. **Cell Host Microbe.** 2020 Dec 21: S1931-3128(20)30663-6. doi: 10.1016/j.chom.2020.12.001. PMID: 33382980.

92. Miller MS, Allen PJ, Brown PH, Chan AT, Clapper ML, Dashwood RH, Demehri S, Disis ML, DuBois RN, Glynn RJ, Kensler TW, Khan SA, Johnson BD, Liby KT, **Lipkin SM**, Mallery SR, Meuillet EJ, Roden RBS, Schoen RE, Sharp ZD, Shirwan H, Siegfried JM, Rao CV, You M, Vilar E, Szabo E, Mohammed A. Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting. **J Cancer Prev.** 2021 Mar 30;26(1):71-82. doi: PMID: 33842408.

93. Waller RG, Klein RJ, Vijai J, McKay JD, Clay-Gilmour A, Wei X, Madsen MJ, Sborov DW, Curtin K, Slager SL, Offit K, Vachon CM, **Lipkin SM**, Dumontet C, Camp NJ. Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes. **Hum Mol Genet.** 2021 Jun 9;30(12):1142-1153. doi: 10.1093/hmg/ddab066.PMID: 33751038.

94. Lencz T, Yu J, Khan RR, Flaherty E, Carmi S, Lam M, Ben-Avraham D, Barzilai N, Bressman S, Darvasi A, Cho JH, Clark LN, Gümüş ZH, Vijai J, Klein RJ, **Lipkin S**, Offit K, Ostrer H, Ozelius LJ, Peter I, Malhotra AK, Maniatis T, Atzmon G, Pe'er I. Novel ultra-rare exonic variants identified in a founder population implicate cadherins in schizophrenia. **Neuron.** 2021 May 5;109(9):1465-1478.e4. PMID: 33756103.

95. Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis. **Gynecol Oncol.** 2021 Aug;162(2):506-516. doi: 10.1016/j.ygyno.2021.05.011. Epub 2021 May 19. PMID: 34023131.

96. Nitecki R, Moss HA, Watson CH, Urbauer DL, Melamed A, Lu KH, **Lipkin SM**, Offit K, Rauh-Hain JA, Frey MK. Facilitated cascade testing (FaCT): a randomized controlled trial. **Int J Gynecol Cancer** 2020 Dec 18:ijgc-2020-002118. PMID: 33443030.

97. Gebert J, Gelincik O, Oezcan-Wahlbrink M, Marshall JD, Hernandez-Sanchez A, Urban K, Long M, Cortes E, Tosti E, Katzenmaier EM, Song Y, Elsaadi A, Deng N, Vilar E, Fuchs V, Nelius N, Yuan YP, Ahadova A, Sei S, Shoemaker RH, Umar A, Wei L, Liu S, Bork P, Edelmann W, von Knebel Doeberitz M, **Lipkin SM***, Kloor M. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model. **Gastroenterology.** 2021 Oct;161(4):1288-1302.e13. doi:

10.1053/j.gastro.2021.06.073. Epub 2021 Jul 2. PMID: 34224739.

98. Wierbowski SD, Liang S, Liu Y, Chen Y, Gupta S, Andre NM, **Lipkin SM**, Whittaker GR, Yu H. A 3D structural SARS-CoV-2-human interactome to explore genetic and drug perturbations. **Nat Methods**. 2021 Dec;18(12):1477-1488. doi: 10.1038/s41592-021-01318-w. PMID: 34845387.

99. Topka S, Steinsnyder Z, Ravichandran V, Tkachuk K, Kemel Y, Bandlamudi C, Winkel Madsen M, Furberg H, Ouerfelli O, Rudin CM, Iyer G, **Lipkin SM**, Mukherjee S, Solit DB, Berger MF, Bajorin DF, Rosenberg JE, Taylor BS, de Stanchina E, Vijai J, Offit K. Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. **Clin Cancer Res**. 2021 Apr 1;27(7):1997-2010. PMID: 33199492.

100. Esai Selvan M, Zauderer MG, Rudin CM, Jones S, Mukherjee S, Offit K, Onel K, Rennert G, Velculescu VE, **Lipkin SM**, Klein RJ, Gümüş ZH. Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk. **J Thorac Oncol.** 2020 Dec;15(12):1871-1879. PMID: 32866655.

101. Chen S, Liu Y, Zhang Y, Wierbowski SD, **Lipkin SM**, Wei X, Yu H. A full-proteome, interaction-specific characterization of mutational hotspots across human cancers. **Genome Res.** 2022 Jan;32(1):135-149. doi: 10.1101/gr.275437.121. PMID: 34963661.

102. Lin J, Wolfe I, Ahsan MD, Krinsky H, Lackner AI, Pelt J, Bolouvi K, Gamble C, Thomas C, Christos PJ, Cantillo E, Holcomb K, Chapman-Davis E, Sharaf R, **Lipkin SM**, Blank SV, Frey MK. Room for improvement in capturing cancer family history in a gynecologic oncology outpatient setting. **Gynecol Oncol Rep**. 2022 Feb 14;40:100941. doi:10.1016/j.gore.2022.100941. PMID:35242980

103. Mukherjee S,…**Lipkin SM**, Belhadj S, Bond GL, Gümüş ZH, Klein RJ, Ladanyi M, Solit DB, Robson ME, Jones DR, Kris MG, Vijai J, Stadler ZK, Amos CI, Taylor BS, Berger MF, Rudin CM, Offit K. Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. **Cancer Epidemiol Biomarkers Prev**. 2022 Apr 27:cebp.EPI-21-1287-A.2021.

104. Hernandez-Sanchez, A., Grossman, M., Yeung, K., Sei, S, **Lipkin, SM**, and Matthias Kloor. Immunoprevention Vaccines. **J Immunotherapy Cancer**. 2022 Jun;10(6):e004416. doi: 10.1136/jitc-2021-004416. PMID: 35732349.

105. Banday, A., Stanifer, M…**Lipkin SM**…Prokunina-Olsson, L. Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries. **Nature Genetics** 2022. https://doi.org/10.1038/s41588-022-01113-z-01113-z

108. Offit, K., Sharkey, C., Green, D., Wu, X., Trottier, M., Hamilton, J., Walsh, M., Dandiker, S., Belhadj, S., **Lipkin**, **SM**, Sugrañes,T., Caggana, M., and Stadler, Z. Regulation of Laboratory-Developed Tests in Preventive Oncology: Emerging Needs and Opportunities. **Journal of Clinical Oncology** J Clin Oncol. 2022 Aug 9: JCO2200995. doi: 10.1200/JCO.22.00995. PMID: 35944238

109. Li, Y., Xu, W., Ren, Y., Cheung, H., Huang, P., Kaur, G., Kuo, C., McDonough, S., Fubini, S., **Lipkin, S**., Deng, X., Chang, Y., and Huang, L. Plakoglobin and HMGB1 mediate intestinal

epithelial cell apoptosis induced by Clostridioides difficile TcdB. **mBio** 10.1128/mbio.01849-22.

110. Dohlman AB, Klug J, Mesko M, Gao IH, **Lipkin SM**, Shen X, Iliev ID. A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors. **Cell**. 2022 Sep 29;185(20):3807-3822.e12. PMID: 36179671.

111. Kahn RM, Ahsan MD, Chapman-Davis E, Holcomb K, Nitecki R, Rauh-Hain JA, Fowlkes RK, Tubito F, Pires M, Christos PJ, Tkachuk K, Krinsky H, Sharaf RN, Offit K, **Lipkin S**, Frey MK. Barriers to completion of cascade genetic testing: how can we improve the uptake of testing for hereditary breast and ovarian cancer syndrome? Fam Cancer. 2022 Oct 8. doi: 10.1007/s10689-022-00316-x. PMID: 36207653.

112. Sei S, Ahadova A, Keskin DB, Bohaumilitzky L, Gebert J, von Knebel Doeberitz M, **Lipkin SM**, Kloor M. Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies. **Front Oncol.** 2023 Mar 22;13:1147590. PMID: 37035178.

113. Viladomiu M, Khounlotham M, Dogan B, Lima SF, Elsaadi A, Cardakli E, Castellanos JG, Ng C, Herzog J, Schoenborn AA, Ellermann M, Liu B, Zhang S, Gulati AS, Sartor RB, Simpson KW, **Lipkin SM**, Longman RS. Agr2-associated ER stress promotes adherent-invasive E. coli dysbiosis and triggers CD103+ dendritic cell IL-23-dependent ileocolitis. **Cell Rep**. 2022 Nov 15;41(7):111637. PMID: 36384110

Reviews and Essays

1. **Lipkin, S.M**., Rosenfeld, M.G., and Glass, C.K. 1992. Regulation of gene expression by thyroid hormones and retinoic acid. **Genetic Engineering** 14:185-209.

2. **Lipkin, S.M.,** and Afrasiabi, K. 2007. Familial colorectal cancer syndrome X. **Seminars in Oncology** 34:425-427.

3. Power, D.G., Gloglowski, E., and **Lipkin, S.M**. 2010. Clinical genetics of hereditary colorectal cancer. **Hematology/Oncology clinics of North America;** 24:837-859.

4. Bu P, Chen KY, **Lipkin SM,** Shen X. Asymmetric division: a marker for cancer stem cells in early stage tumors? **Oncotarget,** 2013 Jul; 4(7)950-1.
Invited commentary on our Cell Stem Cell 2013 publication.

5. Savard, K., and Lipkin, S. My Lynch Syndrome Survivor's Story – Duke "C" Colon Cancer While Pregnant. **Annals of Clinical and Medical Case Reports** 7:2639-8109.

2. Books

1. **SM Lipkin** with Jon Luoma. "The Age of Genomes." Edited H. Atwan. Beacon Press, Boston, MA. 2016.
This book is intended to help educate the lay public on advances and potential roadblocks to the realization of genetic medicine. For reviews and synopses please see https://www.amazon.com/Age-Genomes-Tales-Genetic-Medicine-ebook/dp/B014BQVLV0?ie=UTF8&*Version*=1&*entries*=0#navbar.

3. Book Chapters

1. **Lipkin, SM**, and Offit, K. Clinical Gastrointestinal Cancer Genetics. Gastrointestinal Oncology: Principles and Practices. Edited by David P. Kelsen. Lippincott, Williams & Wilkins, Philadelphia: c2008, Chapter 3.
   This is a popular and well-cited textbook of GI malignancies.

4. Patents

1. Title: A Chemokine Engineered Humanized Mouse Model for Metastatic cancer
   Inventor: **Steven Lipkin**, Xiling Shen, and Huanhuan Chen
   US Patent Application: No. PCT/US13/49302, Cornell University.

2. Title: COMPOSITIONS AND METHODS FOR TREATING LYNCH SYNDROME
   Inventor: **Steven Lipkin**.
   U.S. Patent Application No.: 62/826902



5/24/2023